A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the effect of valsartan on proteinuria and glomerular filtration rate in children with Chronic Kidney Dise...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-001812-65

A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the effect of valsartan on proteinuria and glomerular filtration rate in children with Chronic Kidney Disease who are receiving a standardized dose of angiotensin converting enzyme inhibitor therapy

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the efficacy, safety and tolerability of valsartan versus placebo in children with Chronic Kidney Disease (CKD) manifested by persistent proteinuria (> 500 mg/g) while receiving a standardized dose of ACEI therapy to provide important prescribing information to the pediatrician on the use of valsartan in children with CKD.


Critère d'inclusion

  • Chronic kidney disease is characterized by a progressive decline of glomerular filtration rate (GFR), which occurs irrespectively of the cause of the renal damage once a critical nephron mass has been lost

Liens